EBAY vs ALNY Comparison

Founded in 1995, eBay operates one of the world's largest online marketplaces, connecting buyers and sellers across more than 190 markets. In 2025, the firm generated $11.1 billion in revenue on nearly $80 billion of gross merchandise volume, serving 135 million active buyers and 18 million active sellers (users who closed at least one transaction in the past year). The firm monetizes its marketplace primarily through transaction fees and advertising, with 52% of revenue derived from the US and the remainder from international markets. In a bid to expand its reach among Generation Z and in the recommerce sector, eBay announced the $1.2 billion acquisition of fashion resale app Depop from Etsy in early 2026.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.